373 related articles for article (PubMed ID: 36216931)
21. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
22. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
Khan S; Budamagunta V; Zhou D
Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
[TBL] [Abstract][Full Text] [Related]
23. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
24. Inhibition mechanism of MRTX1133 on KRAS
Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
[TBL] [Abstract][Full Text] [Related]
25. A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA; Han JJW; Lee YH; Lee CS; Luo J
Cancer Res; 2023 Sep; 83(17):2816-2823. PubMed ID: 37339170
[TBL] [Abstract][Full Text] [Related]
26. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract][Full Text] [Related]
27. Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRAS
Orsburn BC
J Proteome Res; 2023 Dec; 22(12):3703-3713. PubMed ID: 37983312
[TBL] [Abstract][Full Text] [Related]
28. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
[TBL] [Abstract][Full Text] [Related]
29. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
[TBL] [Abstract][Full Text] [Related]
30. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
31.
Shen H; Lundy J; Strickland AH; Harris M; Swan M; Desmond C; Jenkins BJ; Croagh D
Cells; 2022 Oct; 11(19):. PubMed ID: 36231137
[No Abstract] [Full Text] [Related]
32. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
Zhou C; Fan Z; Gu Y; Ge Z; Tao Z; Cui R; Li Y; Zhou G; Huo R; Gao M; Wang D; He W; Zheng M; Zhang S; Xu T
J Med Chem; 2024 Jan; 67(2):1147-1167. PubMed ID: 38197882
[TBL] [Abstract][Full Text] [Related]
34. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.
Krantz SB; Shields MA; Dangi-Garimella S; Cheon EC; Barron MR; Hwang RF; Rao MS; Grippo PJ; Bentrem DJ; Munshi HG
Mol Cancer Res; 2011 Oct; 9(10):1294-304. PubMed ID: 21856775
[TBL] [Abstract][Full Text] [Related]
35. A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.
Duan X; Zhang T; Feng L; de Silva N; Greenspun B; Wang X; Moyer J; Martin ML; Chandwani R; Elemento O; Leach SD; Evans T; Chen S; Pan FC
Cell Stem Cell; 2024 Jan; 31(1):71-88.e8. PubMed ID: 38151022
[TBL] [Abstract][Full Text] [Related]
36. Loss of Heterozygosity for
Ma Y; Ling S; Li Y; Hu M; Kong B; Huang P; Liu H
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743139
[TBL] [Abstract][Full Text] [Related]
37. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
38. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
[TBL] [Abstract][Full Text] [Related]
39. D-1553: A novel KRAS
Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
[TBL] [Abstract][Full Text] [Related]
40. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
